Industry Insight
Discovery Technology
Analytical Laboratory Technology
Delivery Systems
Ingredients, Formulation and Finishing
View our other publications with free access to extensive archives


 16th August 2012 Catalent Pharma Solutions

Catalent Announces Commencement of Supply of Abilify® Orally Disintegrating Tablets to Otsuka Pharmaceutical Co. Ltd. and Extensive Investments to it's Zydis® to Technology Capabilities in Swindon, UK

Somerset, NJ, July 24, 2012 - Catalent announced it has commenced supply to Otsuka Pharmaceutical Co., Ltd. of Abilify® OD Tablets (orally disintegrating tablets (ODT)), which utilize Catalent’s Zydis® fast dissolve drug delivery technology.

Otsuka is one of the leading innovative pharmaceutical companies in Japan and has developed Abilify® OD for the treatment of schizophrenia and improvement of manic symptoms associated with bipolar disorder.

Additionally, to support the increasing demand for Zydis® ODT formulations from the Japanese market, Catalent intends to make multi-million dollar investments to its Zydis® ODT operations in Swindon, UK.

Commenting on the new launch and investments, Dr. Ian Muir, President of Catalent’s Modified Release Technology business stated, “We are delighted to partner with Otsuka on the launch of this important new formulation of Abilify® OD. Catalent’s Zydis® fast dissolve technology has provided a tablet that is very palatable, and disintegrates within seconds in the mouth, making it very easy to take. As patient medication compliance is critical for those requiring antipsychotic therapies, Otsuka believes this new formulation will be of great assistance to patients in Japan. Abilify® OD is the 8th drug approved and launched in Japan, using Catalent’s Zydis® ODT.”

Mr. Hans-Joachim Rohe, President of Catalent Japan added, “We are very excited with the growing demand for Catalent’s Zydis® ODT in Japan, where many products could benefit from this type of ODT formulation. We have seen an increasing number of customers specifically seeking truly rapid disintegration and superior palatability in order to differentiate their products in Japan’s competitive market. In this regard, Zydis® ODT can excel over competing alternatives such as loosely compressed tablets.”

Contact Information Email:

About Catalent

Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit

More products. better treatments. reliably supplied.™


Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPT © 2021 Innovations in Pharmaceutical Technology | Terms and Conditions | | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |